Compare SMID & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SMID | STTK |
|---|---|---|
| Founded | 1960 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Building Materials | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 206.7M | 119.0M |
| IPO Year | 1995 | 2020 |
| Metric | SMID | STTK |
|---|---|---|
| Price | $34.39 | $3.10 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 8.6K | ★ 324.5K |
| Earning Date | 11-13-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 81.92 | N/A |
| EPS | ★ 2.22 | N/A |
| Revenue | ★ $88,866,000.00 | $1,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $15.70 | ★ N/A |
| Revenue Growth | ★ 16.37 | N/A |
| 52 Week Low | $25.13 | $0.69 |
| 52 Week High | $50.37 | $3.38 |
| Indicator | SMID | STTK |
|---|---|---|
| Relative Strength Index (RSI) | 48.26 | 71.00 |
| Support Level | $31.52 | $1.93 |
| Resistance Level | $36.50 | $3.30 |
| Average True Range (ATR) | 1.68 | 0.23 |
| MACD | 0.16 | 0.09 |
| Stochastic Oscillator | 57.67 | 80.69 |
Smith-Midland Corp through its subsidiaries invents, develops, manufactures, markets, sells, and installs precast concrete products for primary use in the construction, highway, utilities, and farming industries. The firm's customers are general contractors and federal, state, and local transportation authorities. Its products include Slenderwall, JJhooks, Softsound, Sierra Wall and Easi set. A substantial portion of the company's business is derived from local, state, and federal building projects. The company generates revenues predominantly from the sale, leasing, licensing, shipping, and installation of precast concrete products for the construction, utility, and farming industries.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.